Stock TRVI TREVI THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Delayed Nasdaq
Other stock markets
 16:49:16 29/04/2024 BST 		5-day change 1st Jan Change
2.9 USD +4.32% Intraday chart for Trevi Therapeutics, Inc. -1.36% +116.42%
03-20 Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
03-20 Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
B. Riley Starts Trevi Therapeutics at Buy With $6 PT, Views as Deep Value Play in Idiopathic Pulmonary Fibrosis Chronic Cough Space
MT
JonesTrading Initiates Trevi Therapeutics at Buy With $7 Price Target
MT
SVB Securities Starts Trevi Therapeutics at Outperform With $6 Price Target
MT
Oppenheimer Adjusts Trevi Therapeutics Price Target to $9 From $12 Mainly on Higher Discount Rate, Maintains Outperform Rating
MT
Needham Trims Price Target on Trevi Therapeutics to $8 From $10, Maintains Buy Rating
MT
Oppenheimer Adjusts Trevi Therapeutics' Price Target to $12 From $10, Maintains Outperform Rating
MT
Needham Adjusts Trevi Therapeutics' Price Target to $10 From $8, Reiterates Buy Rating
MT
Trevi Therapeutics Rises After Oppenheimer Starts Coverage With Outperform Rating
MT
Oppenheimer Starts Trevi Therapeutics at Outperform With $10 Price Target
MT
Aegis Capital Initiates Trevi Therapeutics at Buy with $10 Price Target
MT
Needham Adjusts Price Target on Trevi Therapeutics to $8 from $10, Keeps Buy Rating
MT
TREVI THERAPEUTICS : Needham Adjusts Trevi Therapeutics' Price Target to $10 from $12, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRVI Stock
  4. News Trevi Therapeutics, Inc.
  5. Analyst Reco.